BRIEF RESEARCH REPORT
Published on 14 Mar 2025
Cross-Sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethyl
doi 10.3389/fcvm.2025.1411233
- 594 views
- Frontiers in Cardiovascular Medicine
- Cardiovascular Pharmacology and Drug Discovery
- Research Topics
- Therapeutic Strategies to Lower Residual Dyslipidemic CV Risk Beyond LDL-C and Statins
Therapeutic Strategies to Lower Residual Dyslipidemic CV Risk Beyond LDL-C and Statins
5,545
Total downloads
22k
Total views and downloads
Articles
REVIEW
Published on 07 Aug 2024
Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape—focus on hypertriglyceridaemia
doi 10.3389/fcvm.2024.1389106
- 3,221 views
- 9 citations
MINI REVIEW
Published on 13 Mar 2024
Effect of statin add-on therapy on cardiovascular mortality
doi 10.3389/fcvm.2024.1308695
- 2,347 views
- 1 citation
REVIEW
Published on 15 Jan 2024
Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins
doi 10.3389/fcvm.2023.1308173
- 2,026 views
- 1 citation
REVIEW
Published on 31 Aug 2023
Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
doi 10.3389/fcvm.2023.1220017
- 3,906 views
- 2 citations
ORIGINAL RESEARCH
Published on 23 Aug 2023
Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events
doi 10.3389/fcvm.2023.1229130
- 4,450 views
- 9 citations
ORIGINAL RESEARCH
Published on 03 Aug 2023
Quantitative imaging biomarkers of coronary plaque morphology: insights from EVAPORATE
doi 10.3389/fcvm.2023.1204071
- 2,439 views
- 6 citations
